Keywords: ppd, stock, plunges, despite, beating, forecasts, pharmaceutical
PPD stock plunges, despite beating forecasts
Article | 28 July 2003
Pharmaceutical Product Development shares plunged, at one point by as much as 22%, despite the company's second-quarter earnings beating analysts' expectations. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
